It is conceivable that a high frequency of cycling tumour cells in a biopsy taken early in treatment, using, for example, Cyclin B1 as a marker, would predict an increased likelihood of resistance acquisition through this mechanism. The gene discussed is CCNB1; the disease is neoplasm.